Guggenheim Securities Downgrades Aegerion Pharmaceuticals To Sell

Loading...
Loading...
Guggenheim Securities downgraded
Aegerion Pharmaceuticals, Inc.AEGR
from Neutral to Sell. Aegerion Pharmaceuticals shares have dropped 39.92 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period. Aegerion Pharmaceuticals' shares fell 2.47 percent to $18.13 in pre-market trading.
Posted In: DowngradesAnalyst RatingsGuggenheim Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...